Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for IO Biotech, Inc. (IOBT : NSDQ)

• Company Description    IO Biotech Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel, immune-modulating cancer therapies based on its T-win(R) technology platform. IO Biotech Inc. is based in WILMINGTON, Del. Number of Employees: 80

• Price / Volume Information    Yesterday's Closing Price: $0.90 Daily Weekly Monthly 20 Day Moving Average: 5,884,455 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 0.43 52 Week High: $2.79 52 Week Low: $0.32 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 63.32% 59.04% 12 Week -58.26% -59.99% Year To Date -1.99% -14.33%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL OLE MAALOES VEJ 3 - COPENHAGEN,G7 2200 DNK ph: 45-7070-2980 fax: - mci@iobiotech.com http://www.iobiotech.com

• General Corporate Information    Officers Mai-Britt Zocca - Chief Executive Officer and Director Peter Hirth - Chairman of the Board Amy Sullivan - Chief Financial Officer Brian Burkavage - Chief Accounting Officer Kathleen Sereda Glaub - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 449778109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: 0.43 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.25 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 37.31 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -29.03% vs. Previous Quarter: -17.65% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -281.82 03/31/25 - -162.55 ROA 09/30/25 - - 06/30/25 - -169.29 03/31/25 - -125.08 Current Ratio 09/30/25 - - 06/30/25 - 1.96 03/31/25 - 2.32 Quick Ratio 09/30/25 - - 06/30/25 - 1.96 03/31/25 - 2.32 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 0.02 03/31/25 - 0.40 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 4.22 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 80.85 03/31/25 - 0.00

Powered by Zacks Investment Research ©